Glycart Biotechnology AG
Glycart Biotechnology is a Zurich-based start-up that aims to generate antibodies with improved glycosylation characteristics to increase therapeutic potency. The firm's GlycoMAb technology can be applied to customers own cellular production systems to generate more effective versions of existing or experimental antibody therapeutics.
You may also be interested in...
New technologies to characterize and manipulate carbohydrate chemistries and the glycosylation of proteins are spawning viable business models that address what scientists have long known: the sugar coating of proteins and cells is not decorative.
Glycoform Ltd. aims to leverage the pioneering glyco-chemistry research of its Oxford University founders to develop targeted drug delivery systems and to improve the safety and efficacy of protein therapeutics, including monoclonal antibodies, by taking advantage of the way specific oligosaccharides, or sugar motifs, can affect the properties of the proteins they decorate.
By the mid 1990s, most of the early carbohydrate drug development companies were either defunct or had repositioned themselves. But academia continued to advance gycobiology analysis tools. Today, thanks to improved mass spec and bioinformatic methods, as well as newly-revealed structure-activity relationships, a new generation of glycomics companies has a chance to succeed where forebears failed.